Evidence map›Paper›PMID 29635501›Full record

Trial reportThe American journal of clinical nutrition2018

Changes in susceptibility to life-threatening infections after treatment for complicated severe malnutrition in Kenya.

Moses M Ngari, Laura Mwalekwa, Molline Timbwa, Fauzat Hamid, Rehema Ali, Per Ole Iversen, Greg W Fegan, James A Berkley

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal of clinical nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00934492 (Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00934492 phase3completednot on this map

Randomized, Placebo Controlled Trial of Cotrimoxazole Prophylaxis Amongst HIV-uninfected Children With Severe Malnutrition

TypeinterventionalSponsorUniversity of OxfordRan2009 to 2014Enrolled1,781ConditionsNutrition Disorders, Life-threatening InfectionArmsCotrimoxazole dispersible tablet, Placebo dispersible tablet
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Moses M NgariKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Laura MwalekwaKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Molline TimbwaKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Fauzat HamidKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Rehema AliKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Per Ole IversenDepartment of Nutrition, IBM, University of Oslo, Norway.
Greg W FeganKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
James A BerkleyKEMRI/Wellcome Trust Research Programme, Kilifi, Kenya.
Kenya Medical Research Institute · KEOslo University Hospital · NO

Funding

Medical Research Council MR/M007367/1Wellcome TrustWellcome Trust WT083579MA
6 · The paper itself

Abstract

Background: Goals of treating childhood severe acute malnutrition (SAM), in addition to anthropometric recovery and preventing short-term mortality, include reducing the risks of subsequent serious infections. How quickly and how much the risk of serious illness changes during rehabilitation are unknown but could inform improving the design and scope of interventions. Objective: The aim of this study was to investigate changes in the risk of life-threatening events (LTEs) in relation to anthropometric recovery from SAM. Design: This was a secondary analysis of a clinical trial including 1778 HIV-uninfected Kenyan children aged 2-59 mo with complicated SAM, enrolled after the inpatient stabilization phase of treatment, and followed for 12 mo. The main outcome was LTEs, defined as infections requiring rehospitalization or causing death. We examined anthropometric variables measured at months 1, 3, and 6 after enrollment in relation to LTEs occurring during the 6 mo after each of these time points. Results: Over 12 mo, there were 823 LTEs (257 fatal), predominantly severe pneumonia and diarrhea. At months 1, 3, and 6, 557 (34%), 764 (49%), and 842 (56%) children had a weight-for-height or -length z score (WHZ) ≥-2, respectively, which, compared with a WHZ <-3, was associated with lower risks of subsequent LTEs [adjusted HRs (95% CIs): 0.50 (0.40, 0.64), 0.30 (0.23, 0.39), and 0.23 (0.16, 0.32), respectively]. However, children with a WHZ ≥-2 at 1, 3, and 6 mo still had 39 (95% CI: 32, 47), 26 (95% CI: 22, 32), and 15 (95% CI: 12, 20) LTEs/100 child-years of observation during the following 6 mo. WHZ at study enrollment predicted subsequent WHZ but not the risk of LTEs. Changes in height-for-age z score did not predict LTEs. Conclusions: Anthropometric response was associated with a rapid and substantial reduction in risk of LTEs. However, reduction in susceptibility lagged behind anthropometric improvement. Disease events, together with anthropometric assessment, may provide a clearer picture of the effectiveness of interventions. Robust protocols for detecting and treating poor anthropometric recovery and addressing broader vulnerabilities that complicated SAM indicates may save lives. This trial was registered at www.clinicaltrials.gov as NCT00934492.

Indexed as

Child, PreschoolCohort StudiesDisease SusceptibilityFemaleHumansInfantInfant Nutrition DisordersInfectionsKenyaMaleNutritional StatusProtein-Energy MalnutritionRisk FactorsSevere Acute Malnutrition

Identifiers

PMID29635501
PMCPMC6134064
OpenAlexW2796056022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.